SonoVue® 

 

SonoVue® is a second-generation ultrasound contrast agent, designed and optimized for pressure resistance

 

As a result of many years of research and development conducted within Bracco, SonoVue® is a second-generation ultrasound contrast agent designed and optimized with regard to the resistance to pressure.

A quality product from Bracco Imaging

 

As a result of many years of research and development conducted within Bracco, SonoVue® is a second-generation ultrasound contrast agent designed and optimized with regard to the resistance to pressure. The research has led to the selection of SF6, a gas with a low solubility in blood for the gaseous phase of the microbubbles and to a phospholipidic monolayer for the shell. SonoVue® was first approved in the European Union under the centralised procedure on 26 March 2001 and is currently marketed in 36 countries worldwide.

Today SonoVue® can boast more than 1,000 peer review journal articles in the life sciences.

 

 

Physicochemical Characteristics

 

ready-to-use suspension / vial 5 ml
number of microbubbles / ml suspension approx. 2 · 108
gas content (SF 6) / ml suspension 8 μl
mean diameter of microbubbles approx. 2,5 μm
size range of microbubbles 1 - 11 μm (90% < 6 μm, 99% <11 μm)
osmolality approx. 290 mOsmol / Kg
viscosity < 2 mPa · s
pH-value 4,5 - 7,5
stability after preparation 6 hours

Contact us

Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

By checking this box and clicking the submit button of this page, I certify that I am a healthcare professional, and give permission for Bracco Imaging S.p.A., or parties acting on its behalf, to contact me with information regarding Bracco Imaging S.p.A., products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Imaging S.p.A., except for the agents or representatives processing this request.

DISCLAIMER
 

For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully review the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The local Summaries of Product Characteristics of the main Bracco Imaging products are available on line.

SonoVue should not be administered to patients with known hypersensitivity to sulphur hexafluoride or to any of the components of SonoVue. SonoVue is contraindicated for use in patients with recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within last 7 days, significant worsening of cardiac symptoms within last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (for example, recent deterioration of ECG, laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders. SonoVue is contraindicated in patients known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome. The safety and efficacy of SonoVue have not been established in pregnant and lactating women therefore, SonoVue should not be administered during pregnancy and lactation.